公开(公告)号：US06339150B1

公开(公告)日：2002-01-15

申请号：US09137784

申请日：1998-08-21

Applicant: Helmut Bachmayer ,  Ernst Boehnlein ,  Warner C. Greene ,  Joachim Hauber

Inventor： Helmut Bachmayer ,  Ernst Boehnlein ,  Warner C. Greene ,  Joachim Hauber

IPC: C07H2104

CPC classification number: C07K14/005 ,  A61K38/00 ,  C07K16/1036 ,  C12N2740/10022 ,  C12N2740/10043 ,  C12N2740/14022 ,  C12N2740/14043 ,  C12N2740/16322 ,  G03C7/3013 ,  G03C7/36

Abstract: Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II and, in some cases, both the Rev and the Rex function and are, therefore, active in more than one viral species. Such transdominant viral mutants are useful as anti-viral agents to, for example protect cells against the deleterious effects of viral, e.g. HIV-1, infection.

Abstract translation: 衍生自HIV-1的rev基因产物或HTLV-1的rex基因产物和相应的突变基因的具有抑制HIV-1中Rev功能和/或Rex功能的能力的病毒基因表型表达的显性阻遏物 HTLV-I和HTLV-II，在某些情况下，均为Rev和Rex功能，因此在多种病毒物种中活跃。 这样的显性病毒突变体可用作抗病毒剂，例如保护细胞免受病毒的有害影响，例如， HIV-1，感染。

公开(公告)号：US06299874B1

公开(公告)日：2001-10-09

申请号：US09613611

申请日：2000-07-11

Applicant: Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

Inventor： Craig E. Whitfill ,  John A. Thoma ,  Tommy L. Fredericksen ,  Julius K. Tyczkowski ,  J. Paul Thaxton, Jr.

IPC: A61K39395

CPC classification number: C07K16/1036 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/552 ,  C07K16/08 ,  C07K16/081 ,  C12N2720/10034 ,  Y10S435/948

Abstract: A method of producing active immunity against a viral disease in an animal subject comprises administering to the subject a vaccine conjugate consisting essentially of a live virus and a neutralizing factor bound to the live virus. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live virus is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live virus. Preferred subjects are birds, a preferred virus is Infectious Bursal Disease Virus, and a preferred route of administration to birds is by in ovo administration.

Abstract translation: 在动物对象中产生针对病毒性疾病的主动免疫的方法包括向受试者施用基本上由活病毒和与活病毒结合的中和因子组成的疫苗缀合物。 中和因子选自抗体和抗体片段。 活病毒是能够在受试者中产生疾病的活病毒，抗体或抗体片段是能够中和活病毒的物质。 优选的受试者是鸟，优选的病毒是传染性法氏囊病病毒，并且向鸟类施用的优选途径是通过卵内施用。

公开(公告)号：US06251675B1

公开(公告)日：2001-06-26

申请号：US08459898

申请日：1995-06-02

Applicant: Bryan R. Cullen

Inventor： Bryan R. Cullen

IPC: C12N1500

CPC classification number: C07K14/005 ,  A61K38/00 ,  C07K16/1036 ,  C12N2740/10022 ,  C12N2740/10043 ,  C12N2740/14022 ,  C12N2740/14043 ,  C12N2740/16322 ,  G03C7/3013 ,  G03C7/36

Abstract: Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes are described, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. Transient gene expression analysis of a series of missense and deletion mutants has been used. Sane of the mutants found repress both the Rev and the Rex function and are thus active in more than one viral species. Transdominant viral mutants represent a promising new class of anti-viral agents. Cellular expression of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1 infection.

Abstract translation: 描述了衍生自HIV-1的rev基因产物或HTLV-1的rex基因产物和相应的突变基因的病毒基因表型表达的显性阻遏物，其具有抑制HIV-1和/或Rex中的Rev功能的能力 功能在HTLV-I和HTLV-II。 已经使用了一系列错义和缺失突变体的瞬时基因表达分析。突变体的发现抑制了Rev和Rex功能，因此在多种病毒物种中活跃。显性病毒突变体代表了一种有希望的新类型的抗 - 病毒剂。 这些跨主导抑制剂的细胞表达可以用于诸如细胞内免疫的治疗方法中，以保护细胞免受病毒的有害影响，例如， HIV-1感染。

公开(公告)号：US5961984A

公开(公告)日：1999-10-05

申请号：US626452

申请日：1996-04-02

Applicant: Gregory A. Dekaban ,  Jacqueline Arp ,  Steven Kok Hing Foung

Inventor： Gregory A. Dekaban ,  Jacqueline Arp ,  Steven Kok Hing Foung

IPC: A61P31/18 ,  C07K14/15 ,  C07K16/10 ,  A61K39/21 ,  A23J1/00 ,  A61K39/42 ,  C12Q1/70

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C07K2317/21 ,  C12N2740/14022 ,  G01N2333/15 ,  Y10S530/806

Abstract: Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.

Abstract translation: 提供了HTLV-1的分离和纯化的包膜蛋白，没有HTLV-1的非包膜蛋白，并且具有与天然HTLV-1中的包膜蛋白基本相同的构象。 使用双重牛痘/ T7聚合酶系统重组产生蛋白质。 产生蛋白质的非糖基化和糖基化形式。 糖蛋白形式被HTLV-1的包膜蛋白特异的抗体识别。 提供单克隆抗体，其特异性为HTLV-1包膜蛋白，并且与变性形式的HTLV-1包膜蛋白不结合。 HTLV-1包膜蛋白与HTLV-II和STLV的抗体具有交叉反应性。 包膜蛋白可用于HTLV-I和HTLV-II感染的诊断。

公开(公告)号：US5643714A

公开(公告)日：1997-07-01

申请号：US14153

申请日：1993-02-05

Applicant: Kenneth G. Hadlock ,  Chin-Joo Goh ,  Steven K.H. Foung

Inventor： Kenneth G. Hadlock ,  Chin-Joo Goh ,  Steven K.H. Foung

IPC: G01N33/53 ,  A61K38/00 ,  A61K39/00 ,  A61K39/21 ,  C07K7/06 ,  C07K14/15 ,  C07K16/10 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  C12R1/92 ,  G01N33/569 ,  C12Q1/70 ,  C12Q1/68

CPC classification number: C07K7/06 ,  C07K14/005 ,  C07K16/1036 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2740/14022

Abstract: Novel HTLV-I and HTLV-II peptides are disclosed for use in diagnostic assays for detecting and confirming HTLV-I and HTLV-II infection in human sera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp21 envelope protein, and are diagnostic of HTLV-I or HTLV-II infection. The invention also includes an assay kit and method for detecting, and discriminating between, HTLV-I and HTLV-II infection in humans.

Abstract translation: 公开了新型HTLV-I和HTLV-II肽用于诊断测定以检测和确认人血清中的HTLV-1和HTLV-II感染。 肽衍生自HTLV-1和HTLV-II gp21包膜蛋白的类似区域，并且是HTLV-1或HTLV-II感染的诊断。 本发明还包括用于检测和鉴别人类HTLV-1和HTLV-II感染的测定试剂盒和方法。

公开(公告)号：US5164293A

公开(公告)日：1992-11-17

申请号：US587725

申请日：1990-09-25

Applicant: David E. Hofheinz ,  Gary P. Toedter ,  Lori A. Charie ,  Samuel R. Pearlman

Inventor： David E. Hofheinz ,  Gary P. Toedter ,  Lori A. Charie ,  Samuel R. Pearlman

IPC: C07K16/10 ,  G01N33/569

CPC classification number: G01N33/56988 ,  C07K16/1036 ,  Y10S436/811 ,  Y10S436/813

Abstract: A hybrid cell line is provided which is capable of producing monoclonal antibodies which binds to HTLV-I and HTLV-II core antigens p24 and p53; but does not bind the p19 core antigen. The antibody also binds to core antigens of simian T-cell leukemia virus Type I (STLV-I). The monoclonal antibody is identified as the KC-88 monoclonal antibody. The cell line which produces the KC-88 monoclonal antibody has been deposited in the American Type Culture Collection, Rockville, Md. and assigned A.T.C.C. Deposit No. HB 10562.

Abstract translation: 提供能够产生与HTLV-1和HTLV-II核心抗原p24和p53结合的单克隆抗体的杂交细胞系; 但不结合p19核心抗原。 抗体还结合猿猴T细胞白血病病毒I型（STLV-I）的核心抗原。 单克隆抗体被鉴定为KC-88单克隆抗体。 产生KC-88单克隆抗体的细胞系已经保藏在美国罗克维尔的美国典型培养物保藏中心，分配了A.T.C.C. 保藏号HB 10562。

公开(公告)号：US4525300A

公开(公告)日：1985-06-25

申请号：US535115

申请日：1983-09-23

Applicant: Mitsuaki Yoshida ,  Haruo Sugano ,  Fumio Shimizu ,  Kenichi Imagawa

Inventor： Mitsuaki Yoshida ,  Haruo Sugano ,  Fumio Shimizu ,  Kenichi Imagawa

IPC: C07K14/15 ,  C07K16/10 ,  C07C103/52

CPC classification number: C07K14/005 ,  C07K16/1036 ,  C12N2740/14022 ,  Y10S530/806 ,  Y10S930/221

Abstract: An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide selected from the group consisting of:(a) a peptide represented by formula (1):H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H (1)(b) a peptide represented by formula (2):R-Ile-Pro-His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH (2)wherein R is the same as drefined above;(c) a peptide represented by formula (3):R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH (3)wherein R is the same as defined above;(d) a peptide represented by formula (4):H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH (4)(e) a peptide represented by formula (5):R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH (5)wherein R is the same as defined above; and(f) a peptide represented by formula (6):H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH (6)as a hapten, with a carrier in the presence of a hapten-carrier binding agent.

Abstract translation: 通过对哺乳动物体内产生的抗体进行收集而获得的人类白血病病毒相关肽的抗体，其通过向哺乳动物施用通过使人白血病病毒相关肽反应而制备的抗原，所述人白血病病毒相关肽选自：（a） 式（1）表示的肽：H-Tyr-Val-Glu-Pro-Thr-Ala-Pro-Gln-Val-Leu-H（1）（b）由式（2）表示的肽：R-Ile-Pro- His-Pro-Lys-Asn-Ser-Ile-Gly-Gly-Glu-Val-OH（2）其中R与上述精制相同; （c）由式（3）表示的肽：R-Thr-Trp-Thr-Pro-Lys-Asp-Lys-Thr-Lys-Val-Leu-OH（3）其中R与上述定义相同; （d）由式（4）表示的肽：H-Val-Val-Gln-Pro-Lys-Lys-Pro-Pro-Pro-Tyr-OH（4）（e）由式（5）表示的肽： R-Met-Gly-Gln-Ile-Phe-Ser-Arg-Ser-Ala-Ser-Pro-OH（5）其中R与上述定义相同; 和（f）由式（6）表示的肽：作为半抗原的H-Tyr-Pro-Glu-Gly-Thr-Pro-Lys-Asp-Pro-Ile-Leu-Arg-Ser-Leu-OH 在载体中存在半抗原载体结合剂。

公开(公告)号：US4472509A

公开(公告)日：1984-09-18

申请号：US386110

申请日：1982-06-07

Applicant: Otto A. Gansow ,  Mette Strand

Inventor： Otto A. Gansow ,  Mette Strand

IPC: A61K51/10 ,  C07K16/10 ,  C07K16/18 ,  C07K16/30 ,  A61K39/00 ,  A61K39/42 ,  A61K43/00 ,  A61K49/00

CPC classification number: A61K51/1093 ,  C07K16/1036 ,  C07K16/18 ,  C07K16/3015 ,  A61K2121/00 ,  Y10S436/804 ,  Y10S436/811 ,  Y10S436/813 ,  Y10S436/819

Abstract: Methods of manufacturing and purifying metal chelate conjugated monoclonal antibodies are described. The chelated metal may be one which emits alpha, beta or gamma radiation, or positrons. Alternatively, the metal can be one which is fluorogenic or paramagnetic. The conjugates are suited for diagnostic and therapeutic uses.

Abstract translation: 描述了制备和纯化金属螯合物共轭单克隆抗体的方法。 螯合金属可以是发射α，β或γ辐射的金属或正电子。 或者，金属可以是荧光或顺磁性的金属。 缀合物适用于诊断和治疗用途。

公开(公告)号：US20190218276A1

公开(公告)日：2019-07-18

申请号：US16087036

申请日：2016-10-27

Applicant: THE BROAD INSTITUTE, INC. ,  MASSACHUSETTS INSTITUTE OF TECHNOLOGY ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Aviv Regev ,  Feng Zhang ,  Naomi Habib ,  Yinqing Li ,  Matthias Heidenreich ,  Lukasz Swiech ,  Anindita Basu ,  David Weitz ,  Inbal Avraham Davidi

IPC: C07K16/10 ,  C12N15/10 ,  C12Q1/686 ,  C12Q1/6869

CPC classification number: C07K16/1036 ,  C12N15/1093 ,  C12N15/1096 ,  C12Q1/686 ,  C12Q1/6869 ,  C12Q2537/165 ,  C12Q2563/179 ,  C12Q2565/514 ,  C12Q2565/629

Abstract: Transcriptomes of individual neurons provide rich information about cell types and dynamic states. However, it is difficult to capture rare dynamic processes, such as adult neurogenesis, because isolation from dense adult tissue is challenging, and markers for each phase are limited. Here, Applicants developed Nuc-seq, Div-Seq, and Dronc-Seq. Div-seq combines Nuc-Seq, a scalable single nucleus RNA-Seq method, with EdU-mediated labeling of proliferating cells. Nuc-Seq can sensitively identify closely related cell types within the adult hippocampus. Div-Seq can track transcriptional dynamics of newborn neurons in an adult neurogenic region in the hippocampus. Dronc-Seq uses a microfluidic device to co-encapsulate individual nuclei in reverse emulsion aqueous droplets in an oil medium together with one uniquely barcoded mRNA-capture bead. Finally, Applicants found rare adult newborn GABAergic neurons in the spinal cord, a non-canonical neurogenic region. Taken together, Nuc-Seq, Div-Seq and Dronc-Seq allow for unbiased analysis of any complex tissue.

公开(公告)号：US09550824B2

公开(公告)日：2017-01-24

申请号：US14221963

申请日：2014-03-21

Applicant: GENEURO SA

Inventor： Corinne Bernard ,  Alois Bernhardt Lang ,  Herve Perron ,  Jean-Baptiste Bertrand

IPC: A61K39/395 ,  C07K16/10 ,  A61K39/00

CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.

Abstract translation: 配体包括SEQ ID No.1，SEQ ID No.2，SEQ ID No.3，SEQ ID No.4，SEQ ID No.5和SEQ ID No.6所示的每个互补决定区（CDR） 或在CDR1（SEQ ID No.1）中为0〜3，CDR2（SEQ ID No.2）为0〜2，0〜2的任意序列，在所述序列内具有任意数量的取代氨基酸的序列， 在CDR3（SEQ ID No.3）中，在CDR4（SEQ ID No.4）中为0至1，CDR5（SEQ ID No.5）为0至4，CDR6为0至2（SEQ ID No.6 ）或在所述序列SEQ ID No.1至SEQ ID No.6内具有等同化学功能和性质的其它氨基酸取代的氨基酸。